Asthma Treatment Standard Set
Cayman Chemical Item Number 10008640
Asthma Treatment Standard Set
Description
The Cayman Asthma Treatment Standard Set contains three potent, selective Cysteinyl Leukotriene (CysLT) 1 receptor antagonists (10 mg each) currently used clinically for the treatment of asthma. Zafirlukast and Montelukast (sodium salt), sold under the trade names Accolate and Singulair, respectively, are used for the treatment of asthma as well as for the symptoms associated with allergic rhinitis.1,2,3 Pranlukast, sold under the trade name Ultair, was the first CysLT receptor antagonist marketed for the treatment of asthma.4,5 In addition to these three CysLT1 receptor antagonists, the asthma pak also includes Zileuton, which is supplied free of charge. Zileuton is a reversible 5-LO inhibitor that was approved in 1997 for the prevention and treatment of asthma in the USA, but was withdrawn by Abbott Laboratories in 2003.6,7
1
Matassa, V.G., Maduskuie, T.P., Shapiro, H.S., et al. Evolution of a series of peptidoleukotriene antagonists: Synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles. J Med Chem 33 1781-1790 (1990).
2
Silverman, R.A., Nowak, R.M., Korenblat, P.E., et al. Zafirlukast treatment for acute asthma. Evaluation in a randomized, double-blind, multicenter trail. Chest 126 1480-1489 (2004).
3
Peters-Golden, M., and Henderson, W.R. The role of leukotrienes in allergic rhinitis. Ann Allergy Asthma Immunol 94 609-618 (2005).
4
Barnes, N.C., de Jong, B., and Miyamoto, T. Worldwide clinical experience with the first marketed leukotriene receptor antagonist. Chest 111 52-60 (1997).
5
Taniguchi, Y., Tamura, G., Honma, M., et al. The effect of an oral leukotriene antagonist ONO-1078, on allergen-induced immediate bronchoconstriction. J Allergy Clin Immunol 92 507-512 (1993).
6
Carter, G.W., Young, P.R., Albert, D.H., et al. 5-Lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 256 929-937 (1991).
7
Zouboulis, C.C., Saborowski, A., and Boschnakow, A. Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production. Dermatology 210 36-38 (2005).
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
Wet ice
in continental US; may vary elsewhere
|
Background Reading
Carter, G.W., Young, P.R., Albert, D.H., et al. 5-Lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 256 929-937 (1991).
Peters-Golden, M., and Henderson, W.R. The role of leukotrienes in allergic rhinitis. Ann Allergy Asthma Immunol 94 609-618 (2005).
Barnes, N.C., de Jong, B., and Miyamoto, T. Worldwide clinical experience with the first marketed leukotriene receptor antagonist. Chest 111 52-60 (1997).
Taniguchi, Y., Tamura, G., Honma, M., et al. The effect of an oral leukotriene antagonist ONO-1078, on allergen-induced immediate bronchoconstriction. J Allergy Clin Immunol 92 507-512 (1993).
Silverman, R.A., Nowak, R.M., Korenblat, P.E., et al. Zafirlukast treatment for acute asthma. Evaluation in a randomized, double-blind, multicenter trail. Chest 126 1480-1489 (2004).
Matassa, V.G., Maduskuie, T.P., Shapiro, H.S., et al. Evolution of a series of peptidoleukotriene antagonists: Synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles. J Med Chem 33 1781-1790 (1990).
Show all 6
Hide all but first 3
|
Pricing updated 2012-05-25.
Prices are subject to change without notice.
To ask for assistance with one of our products please contact a Technical Support Scientist.
Warning This product is not for human or veterinary use.
Downloads
Batch-specific Information
Login
to access batch-specific information
|